Oncological and Reproductive Outcomes of Fertility-sparing Surgery in Women with Early-stage Epithelial Ovarian Carcinoma: A Multicenter Retrospective Study

Abstract

With delayed childbearing in women, preservation of fertility is an important issue for reproductive-age patients with epithelial ovarian carcinoma (EOC). Fertility-sparing surgery (FSS) can be considered in patients with early-stage disease in order to preserve fertility and improve quality of life. In order to evaluate oncological safety, attitudes toward childbearing and reproductive outcomes in women with EOC who underwent FSS, this multicenter retrospective study was conducted. Between January 2005 and December 2014, total of 87 young women with FIGO stage I EOC were included, with their clinicopathologic parameters in relation to disease-free survival (DFS) and overall survival (OS) assessed. Attitudes toward childbearing, ovarian function and fertility were studied in women undergoing FSS (n=36). As a result, in contrast to radical surgery, FSS did not affect prognosis by Kaplan-Meier curves (log-rank test; DFS: P=0.484; OS: P=0.125). However, two of the three recurrence cases and both death cases were in FSS group stage IC. All women undergoing FSS resumed regular menstrual periods after chemotherapy. Only 16 (44.44%) had tried to conceive, and 17 pregnancies occurred in 15 (93.75%) women. Among 20 women who did not attempt conception, the most common reason was not being married (70%), followed by already having children (15%). In summary, FSS is considered safe in young women with stage IA EOC. Regular menstruation and good obstetric outcomes can be achieved. This study also provides some insight into the attitudes and social factors regarding fertility in EOC patients.

Keywords

epithelial ovarian cancer / fertility outcome / fertility preservation / fertility sparing surgery / ovarian function

References

[1] SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34

[2] GreenleeRT, Hill-HarmonMB, et al.. Cancer statistics, 2001. CA Cancer J Clin, 2001, 51(1): 15-36

[3] WrightJD, ShahM, MathewL, et al.. Fertility preservation in young women with epithelial ovarian cancer. Cancer, 2009, 115(18): 4118-4126

[4] BergaminiA, PetroneM, RabaiottiE, et al.. Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues. Gynecol Endocrinol, 2018, 34(4): 305-308

[5] HeintzAP, OdicinoF, MaisonneuveP, et al.. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 2006, 95(Suppl 1): S161-192

[6] LacombeD, BrandesAA, van den BentM. The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors. Semin Oncol, 2003, 30(6 Suppl 19): 77-80

[7] RosendahlM, HogdallCK, MosgaardBJ. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Int J Gynecol Cancer, 2016, 26(4): 680-687

[8] SatohT, HataeM, WatanabeY, et al.. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol, 2010, 28(10): 1727-1732

[9] KajiyamaH, MizunoM, ShibataK, et al.. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study. Eur J Obstet Gynecol Reprod Biol, 2014, 175: 97-102

[10] HedbackNE, KarlsenMA, HogdallCK, et al.. Survival of selected patients with ovarian cancer treated with fertility-sparing surgery. Reprod Biomed Online, 2018, 37(1): 71-76

[11] MelamedA, RizzoAE, NiteckiR, et al.. All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstet Gynecol, 2017, 130(1): 71-79

[12] BentivegnaE, MoriceP, UzanC, et al.. Fertility-sparing surgery in epithelial ovarian cancer. Future Oncol, 2016, 12(3): 389-398

[13] ZapardielI, DiestroMD, AlettiG. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol, 2014, 40(4): 387-393

[14] Masoumi-MoghaddamS, AminiA, WeiAQ, et al.. Sprouty 1 predicts prognosis in human epithelial ovarian cancer. Am J Cancer Res, 2015, 5(4): 1531-1541

[15] AebiS, CastiglioneM, GroupEGW. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, 19(Suppl 2): ii14-ii16

[16] MorganRJJr., AlvarezRD, ArmstrongDK, et al.. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw, 2012, 10(11): 1339-1349

[17] FruscioR, CorsoS, CeppiL, et al.. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol, 2013, 24(1): 138-144

[18] DittoA, MartinelliF, LorussoD, et al.. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol, 2014, 25(4): 320-327

[19] JiangX, YangJ, YuM, et al.. Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World J Surg Oncol, 2017, 15(1): 154

[20] DittoA, MartinelliF, BoganiG, et al.. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol, 2015, 138(1): 78-82

[21] BentivegnaE, FruscioR, RoussinS, et al.. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril, 2015, 104(5): 1319-1324

[22] YinJ, WangY, ShanY, et al.. Pregnancy and oncologic outcomes of early stage low grade epithelial ovarian cancer after fertility sparing surgery: a retrospective study in one tertiary hospital of China. J Ovarian Res, 2019, 12(1): 44

[23] NoyesN, LabellaPA, GrifoJ, et al.. Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. J Assist Reprod Genet, 2010, 27(8): 495-499

[24] MooreHC, UngerJM, PhillipsKA, et al.. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med, 2015, 372(10): 923-932

[25] FrancisPA, ReganMM, FlemingGF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med, 2015, 372(17): 1673